blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2157101

EP2157101 - HSP peptides and analogs for modulation of immune responses via antigen presenting cells [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  31.07.2015
Database last updated on 25.09.2024
Most recent event   Tooltip13.10.2017Lapse of the patent in a contracting state
New state(s): BG, HU, TR		published on 15.11.2017  [2017/46]
Applicant(s)For all designated states
Andromeda Bio Tech Ltd.
Building No. 16 Kiryat Weizmann
76326 Rehovot / IL
[2010/08]
Inventor(s)01 / Karmon, Yoram
6 Martin Buber Street
49407 Petah Tikva / IL
02 / Avron, Ann
Gordon Street 49/4
76286 Rehvot / IL
03 / Elias, Dana
Zevulon Street 14
70700 Gedera / IL
 [2010/08]
Representative(s)Straus, Alexander
Patentanwälte
Becker, Kurig, Straus
Bavariastrasse 7
80336 München / DE
[2014/39]
Former [2010/08]Straus, Alexander
Patentanwälte Becker, Kurig, Straus Bavariastrasse 7
80336 München / DE
Application number, filing date09005836.330.01.2003
[2010/08]
Priority number, dateUS20020352594P31.01.2002         Original published format: US 352594 P
[2010/08]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2157101
Date:24.02.2010
Language:EN
[2010/08]
Type: B1 Patent specification 
No.:EP2157101
Date:24.09.2014
Language:EN
[2014/39]
Search report(s)(Supplementary) European search report - dispatched on:EP15.01.2010
ClassificationIPC:G01N33/68, G01N33/50, A61K49/00, A61K38/00, C07K14/47
[2014/19]
CPC:
G01N33/6863 (EP,US); A61K49/0004 (EP,US); C07K14/47 (EP,US);
C07K14/4713 (EP,US); G01N33/5008 (EP,US); G01N33/5011 (EP,US);
G01N33/502 (EP,US); G01N33/5047 (EP,US); G01N33/505 (EP,US);
G01N33/5091 (EP,US); A61K38/00 (EP,US); C07K2319/00 (EP,US) (-)
Former IPC [2010/08]C07K14/47, A61K35/12
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SI,   SK,   TR [2010/08]
TitleGerman:HSP-Peptide und Analoga zur Modulation von Immunantworten mittels antigenpräsentierenden Zellen[2010/08]
English:HSP peptides and analogs for modulation of immune responses via antigen presenting cells[2010/08]
French:Peptides HSP et analogues pour la modulation de réponses immunes via des cellules présentant l'antigène[2010/08]
Examination procedure01.07.2009Examination requested  [2010/08]
06.09.2010Despatch of a communication from the examining division (Time limit: M04)
27.12.2010Reply to a communication from the examining division
29.12.2011Despatch of a communication from the examining division (Time limit: M04)
19.04.2012Reply to a communication from the examining division
29.11.2012Despatch of a communication from the examining division (Time limit: M04)
05.03.2013Reply to a communication from the examining division
25.04.2014Communication of intention to grant the patent
12.08.2014Fee for grant paid
12.08.2014Fee for publishing/printing paid
12.08.2014Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP03702990.7  / EP1575479
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20030702990) is  16.12.2008
Opposition(s)25.06.2015No opposition filed within time limit [2015/36]
Fees paidRenewal fee
27.04.2009Renewal fee patent year 03
27.04.2009Renewal fee patent year 04
27.04.2009Renewal fee patent year 05
27.04.2009Renewal fee patent year 06
27.04.2009Renewal fee patent year 07
25.01.2010Renewal fee patent year 08
31.01.2011Renewal fee patent year 09
26.01.2012Renewal fee patent year 10
31.01.2013Renewal fee patent year 11
31.01.2014Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.01.2003
AT24.09.2014
BG24.09.2014
CY24.09.2014
CZ24.09.2014
DK24.09.2014
EE24.09.2014
FI24.09.2014
MC24.09.2014
NL24.09.2014
SE24.09.2014
SI24.09.2014
SK24.09.2014
TR24.09.2014
GR25.12.2014
PT26.01.2015
IE30.01.2015
LU30.01.2015
BE31.01.2015
CH31.01.2015
LI31.01.2015
[2017/39]
Former [2016/12]AT24.09.2014
CY24.09.2014
CZ24.09.2014
DK24.09.2014
EE24.09.2014
FI24.09.2014
MC24.09.2014
NL24.09.2014
SE24.09.2014
SI24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
IE30.01.2015
LU30.01.2015
BE31.01.2015
CH31.01.2015
LI31.01.2015
Former [2016/07]AT24.09.2014
CY24.09.2014
CZ24.09.2014
DK24.09.2014
EE24.09.2014
FI24.09.2014
MC24.09.2014
NL24.09.2014
SE24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
IE30.01.2015
LU30.01.2015
BE31.01.2015
CH31.01.2015
LI31.01.2015
Former [2015/47]AT24.09.2014
CY24.09.2014
CZ24.09.2014
DK24.09.2014
EE24.09.2014
FI24.09.2014
MC24.09.2014
NL24.09.2014
SE24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
LU30.01.2015
BE31.01.2015
CH31.01.2015
LI31.01.2015
Former [2015/43]AT24.09.2014
CY24.09.2014
CZ24.09.2014
DK24.09.2014
EE24.09.2014
FI24.09.2014
MC24.09.2014
NL24.09.2014
SE24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
LU30.01.2015
BE31.01.2015
Former [2015/39]AT24.09.2014
CY24.09.2014
CZ24.09.2014
DK24.09.2014
EE24.09.2014
FI24.09.2014
NL24.09.2014
SE24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
LU30.01.2015
BE31.01.2015
Former [2015/35]AT24.09.2014
CY24.09.2014
CZ24.09.2014
DK24.09.2014
EE24.09.2014
FI24.09.2014
NL24.09.2014
SE24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
BE31.01.2015
Former [2015/30]AT24.09.2014
CY24.09.2014
CZ24.09.2014
EE24.09.2014
FI24.09.2014
NL24.09.2014
SE24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
BE31.01.2015
Former [2015/25]AT24.09.2014
CY24.09.2014
CZ24.09.2014
EE24.09.2014
FI24.09.2014
NL24.09.2014
SE24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
Former [2015/23]CY24.09.2014
CZ24.09.2014
EE24.09.2014
FI24.09.2014
NL24.09.2014
SE24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
Former [2015/22]CY24.09.2014
FI24.09.2014
NL24.09.2014
SE24.09.2014
GR25.12.2014
PT26.01.2015
Former [2015/16]CY24.09.2014
FI24.09.2014
NL24.09.2014
SE24.09.2014
GR25.12.2014
Former [2015/11]CY24.09.2014
FI24.09.2014
SE24.09.2014
GR25.12.2014
Former [2015/09]FI24.09.2014
SE24.09.2014
Documents cited:Search[A]US6180103  (COHEN IRUN R [IL], et al) [A] 1-7 * the whole document * * SEQ ID NO:8 is identical to SEQ ID NO:3 of the current application *;
 [A]  - BINDER R J ET AL, "Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 DEC 2000, (20001201), vol. 165, no. 11, ISSN 0022-1767, pages 6029 - 6035, XP002390148 [A] 1-7 * the whole document *
 [A]  - SINGH-JASUJA HARPREET ET AL, "The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, (200008), vol. 30, no. 8, ISSN 0014-2980, pages 2211 - 2215, XP002174948 [A] 1-7 * the whole document *

DOI:   http://dx.doi.org/10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0
 [A]  - RAZ I ET AL, "beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial", LANCET THE, LANCET LIMITED. LONDON, GB, (20011124), vol. 358, no. 9295, ISSN 0140-6736, pages 1749 - 1753, XP004805546 [A] 1-7 * discloses the peptide sequence of DiaPep277, which is identical to SEQ ID NO:3 of the current application; page 1750 *

DOI:   http://dx.doi.org/10.1016/S0140-6736(01)06801-5
by applicantEP0262710
 WO8912455
 WO9102542
 EP0417271
 WO9204049
 US5114844
 WO9402509
 US5348945
 WO9429459
 WO9525744
 WO9610039
 WO9611948
 WO9616083
 WO9618646
 WO9619236
 WO9632957
 US5578303
 WO9701959
 WO9711966
 JPH09241159
 US5671848
 WO9808536
 US5736146
 US5780034
 JPH10212230
 US5869058
 US5958416
 US5985270
 US5993803
 WO0027870
 US6110746
 US6180103
 WO0143691
 US6322790
    - JINDAL ET AL., MOL CELL BIOL., (1989), vol. 9, page 2279
    - BECKER J.; CRAIG A. E., EUR. J. BIOCHEM., (1994), vol. 219, page 11
    - VAN EDEN ET AL., IMMUNOLOGY TODAY, (1998), vol. 19, page 303
    - ELIAS ET AL., PROC. NATL. ACAD. SCI., (1991), vol. 88, page 3088
    - BIRK ET AL., PROC NATL ACAD SCI, (1996), vol. 93, page 1032
    - VAN EDEN ET AL., NATURE, (1988), vol. 331, page 171
    - BIRK ET AL., PROC NATL ACAD SCI, (1999), vol. 96, page 5159
    - CHEN ET AL., J. IMMUNOL., (1999), vol. 162, page 3212
    - OHASHI ET AL., J. IMMUNOL., (2000), vol. 164, pages 558 - 61
    - JANEWAY ET AL., PROC. NAT. ACAD. SCI., (2001), vol. 98, pages 7461 - 7468
    - COLIN C. A.; MATZINGER P., SEMINARS IN IMMUNOLOGY, (2001), vol. 12, pages 231 - 238
    - RE, F.; STROMINGER, J. L., "Toll-like receptor 2 (Tlr2) and Tlr4 differentially activate human dendritic cells", J BIOL CHEM, (2001), vol. 276, pages 37692 - 9
    - PILLAI ET AL., CURR. OPIN. CHEM. BIOL., (2001), vol. 5, page 447
    - FINGL ET AL., The Pharmacological Basis of Therapeutics, (1975), page L
    - WHELAN ET AL., J. IMMUNOL, (2000), vol. 164, pages 6453 - 6460
    - J BIOL CHEM, vol. 276, pages 37692 - 9
    - OHKAWARA ET AL., GASTROENTEROLOGY, (2002), vol. 123, pages 256 - 70
    - MAHLER ET AL., GENOMICS, (1999), vol. 55, pages 147 - 56
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.